Environmental risk assessment of replication competent viral vectors applied in clinical trials: potential effects of inserted sequences.

Risk assessments of clinical applications involving genetically modified viral vectors are carried out according to general principles that are implemented in many national and regional legislations, e.g., in Directive 2001/18/EC of the European Union.

Cultivated microalgae spills: hard to predict/easier to mitigate risks.

Cultivating algae on a large scale will inevitably lead to spills into natural ecosystems. Most risk analyses have dealt only with transgenic algae, without considering the risks of cultivating the corresponding non-transgenic wild type species. This is despite the long-studied 'paradox of the plankton', which describes the unsuitability of laboratory experimentation or modeling to predict the outcome of introducing non-native algae into a new ecosystem.

General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.

This introductory paper gathers general considerations on the biosafety of virus-derived vectors that are used in human gene therapy and/or vaccination. The importance to assess the potential risks for human health and the environment related to the use of genetically modified organisms (GMO) in this case genetically modified viral vectors is highlighted by several examples. This environmental risk assessment is one of the requirements within the European regulatory framework covering the conduct of clinical trials using GMO.

Animal models in virus research: their utility and limitations.

Viral diseases are important threats to public health worldwide. With the number of emerging viral diseases increasing the last decades, there is a growing need for appropriate animal models for virus studies. The relevance of animal models can be limited in terms of mimicking human pathophysiology.

Emergence of viral diseases: mathematical modeling as a tool for infection control, policy and decision making.

Mathematical modeling can be used for the development and implementation of infection control policy to combat outbreaks and epidemics of communicable viral diseases. Here an outline is provided of basic concepts and approaches used in mathematical modeling and parameterization of disease transmission. The use of mathematical models is illustrated, using the 2001 UK foot-and-mouth disease (FMD) epidemic, the 2003 global severe acute respiratory syndrome (SARS) epidemic, and human influenza pandemics, as examples.

Reappraisal of biosafety risks posed by PERVs in xenotransplantation.

Donor materials of porcine origin could potentially provide an alternative source of cells, tissues or whole organs for transplantation to humans, but is hampered by the health risk posed by infection with porcine viruses. Although pigs can be bred in such a way that all known exogenous microorganisms are eliminated, this is not feasible for all endogenous pathogens, such as the porcine endogenous retroviruses (PERVs) which are present in the germline of pigs as proviruses. Upon transplantation, PERV proviruses would be transferred to the human recipient along with the xenograft.

Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines.

All living organisms are continuously exposed to a plethora of viruses. In general, viruses tend to be restricted to the natural host species which they infect. From time to time viruses cross the host-range barrier expanding their host range.